Aquestive Therapeutics (AQST) News Today $2.83 -0.17 (-5.67%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$2.84 +0.01 (+0.21%) As of 05/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Invesco Ltd. Reduces Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Invesco Ltd. cut its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 93.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 47,944 shares of the company's stock after selling 738,635 shares during the quarterMay 6 at 3:22 AM | marketbeat.comJPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)JPMorgan Chase & Co. cut its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 80.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,500 shares of the company's stMay 5 at 3:06 AM | marketbeat.comAquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside PotentialMay 4 at 5:03 PM | seekingalpha.comAquestive Therapeutics (AQST) Expected to Announce Earnings on TuesdayAquestive Therapeutics (NASDAQ:AQST) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-aquestive-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comAquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ETMay 1, 2025 | globenewswire.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of "Buy" from AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been given a consensus recommendation of "Buy" by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating tApril 27, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Holdings Lowered by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP lowered its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 26.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 900,000 shares of the company's stockApril 26, 2025 | marketbeat.comFranklin Resources Inc. Reduces Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Franklin Resources Inc. decreased its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,134,796 shares of the company's stock afApril 12, 2025 | marketbeat.comAquestive Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumApril 9, 2025 | globenewswire.comRaymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Raymond James Financial Inc. purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 139,591 shares of the company's stock, valuedApril 9, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for AQST Q1 Earnings?Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Aquestive Therapeutics in a report released on Wednesday, April 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings perApril 8, 2025 | marketbeat.comAquestive Therapeutics (NASDAQ:AQST) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday.April 4, 2025 | marketbeat.comAquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual FilmApril 3, 2025 | seekingalpha.comAquestive Therapeutics (AQST) Gets a Buy from Lake StreetApril 2, 2025 | markets.businessinsider.comAquestive announces positive results from pediatric study for AnaphylmApril 2, 2025 | markets.businessinsider.comAquestive completes marketing application for Anaphylm in U.S.April 1, 2025 | msn.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Position Lowered by Everstar Asset Management LLCEverstar Asset Management LLC trimmed its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 46.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 216,223 shares of the company's stock after seApril 1, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of "Buy" from AnalystsAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has earned a consensus recommendation of "Buy" from the eight research firms that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assignedMarch 31, 2025 | marketbeat.comEntryPoint Capital LLC Acquires 112,210 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)EntryPoint Capital LLC increased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 475.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,797 shares of the company's stocMarch 27, 2025 | marketbeat.comAquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyMarch 25, 2025 | seekingalpha.comAquestive Therapeutics: Not For Me, But AttractiveMarch 24, 2025 | seekingalpha.comAnalysts Offer Predictions for AQST FY2026 EarningsAquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - HC Wainwright issued their FY2026 earnings per share estimates for Aquestive Therapeutics in a research note issued on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.56)March 12, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for AQST Q1 Earnings?Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued to clients and investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju expectsMarch 12, 2025 | marketbeat.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comAquestive Therapeutics (NASDAQ:AQST) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Monday.March 10, 2025 | marketbeat.comEarnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their ForecastsMarch 8, 2025 | uk.finance.yahoo.comAquestive Therapeutics (NASDAQ:AQST) Price Target Cut to $8.00 by Analysts at Lake Street CapitalLake Street Capital reduced their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Friday.March 8, 2025 | marketbeat.comRaymond James Keeps Their Buy Rating on Aquestive Therapeutics (AQST)March 7, 2025 | markets.businessinsider.comAquestive Therapeutics price target lowered to $7 from $8 at Raymond JamesMarch 7, 2025 | markets.businessinsider.comAquestive Therapeutics Inc (AQST) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...March 7, 2025 | finance.yahoo.comAlliance Global Partners Reaffirms Their Buy Rating on Aquestive Therapeutics (AQST)March 7, 2025 | markets.businessinsider.comAquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global PartnersMarch 7, 2025 | markets.businessinsider.comAquestive Therapeutics Reports 2024 Financial Results and Strategic ProgressMarch 6, 2025 | tipranks.comAquestive Therapeutics sees FY25 revenue $47M-$56M , consensus $52.97MMarch 6, 2025 | markets.businessinsider.comAquestive Therapeutics (NASDAQ:AQST) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPSAquestive Therapeutics (NASDAQ:AQST - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.05).March 6, 2025 | marketbeat.comAquestive Therapeutics misses Q4 estimates, shares fallMarch 6, 2025 | uk.investing.comAquestive Therapeutics misses Q4 estimates, shares fallMarch 6, 2025 | uk.investing.comAquestive Therapeutics reports Q4 EPS (19c), consensus (13c)March 6, 2025 | markets.businessinsider.comAquestive Therapeutics reports Q4 EPS (19c), consensus (13c)March 6, 2025 | markets.businessinsider.comAquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver LiningsMarch 6, 2025 | msn.comAquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver LiningsMarch 6, 2025 | msn.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from BrokeragesAquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has received a consensus recommendation of "Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommMarch 6, 2025 | marketbeat.comAquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5, 2025 | globenewswire.comAquestive Therapeutics Q4 2024 Earnings PreviewMarch 4, 2025 | msn.comAquestive Therapeutics to Participate in Two Upcoming Conferences in MarchFebruary 26, 2025 | markets.businessinsider.comAquestive Therapeutics (AQST) to Release Earnings on WednesdayAquestive Therapeutics (NASDAQ:AQST) will be releasing earnings after the market closes on Wednesday, March 5, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=637658)February 26, 2025 | marketbeat.comShort Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Decreases By 5.9%Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the target of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 11,090,000 shares, a decline of 5.9% from the January 15th total of 11,790,000 shares. Based on an average daily trading volume, of 1,470,000 shares, the short-interest ratio is presently 7.5 days.February 18, 2025 | marketbeat.comAquestive Therapeutics to present new findings at AAAAI meetingFebruary 12, 2025 | markets.businessinsider.comHarvey Capital Management Inc. Has $952,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)Harvey Capital Management Inc. grew its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 1,419.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 267,390 shares of the company'February 12, 2025 | marketbeat.comAquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual MeetingFebruary 12, 2025 | globenewswire.com Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Media Mentions By Week AQST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AQST News Sentiment▼0.950.72▲Average Medical News Sentiment AQST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AQST Articles This Week▼43▲AQST Articles Average Week Get Aquestive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AUPH News ETNB News WVE News ELVN News XFOR News ZYME News PHVS News SYRE News MLYS News NTLA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AQST) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AQST Stock Free AQST Stock Alerts